FLT3 and acute myeloid leukemia: However, relapse still frequently occurs after treatment with these inhibitors, often due to activating mutations in other signaling genes.7 The identification of other druggable targets in FLT3-ITD+ AML is therefore necessary to improve the outcome of patients.